Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Ascendis Pharma A/S (ADR) - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ASND
Nasdaq
8731
https://ascendispharma.dk/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Ascendis Pharma A/S (ADR)
Two Health Care Stocks Outperform S&P 500, Offer Entries
- Mar 22nd, 2024 4:09 pm
Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?
- Mar 22nd, 2024 1:40 pm
Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?
- Mar 22nd, 2024 11:47 am
Ascendis Pharma A/S (ASND) Rose on Positive Trial Results
- Mar 22nd, 2024 9:27 am
30 Biggest Biotechnology Companies in the World
- Mar 17th, 2024 12:50 pm
The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys
- Mar 11th, 2024 2:36 pm
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
- Mar 8th, 2024 12:31 pm
Ascendis Pharma A/S (ASND) Faced R&D Setbacks in Q4
- Mar 7th, 2024 1:14 pm
Is AdaptHealth (AHCO) Stock Outpacing Its Medical Peers This Year?
- Mar 6th, 2024 2:40 pm
Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024
- Mar 4th, 2024 1:30 pm
Ascendis Pharma A/S (ASND) is a Great Momentum Stock: Should You Buy?
- Feb 15th, 2024 5:00 pm
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?
- Feb 15th, 2024 2:40 pm
US$172 - That's What Analysts Think Ascendis Pharma A/S (NASDAQ:ASND) Is Worth After These Results
- Feb 10th, 2024 12:12 pm
Ascendis Pharma A/S (NASDAQ:ASND) Q4 2023 Earnings Call Transcript
- Feb 8th, 2024 3:07 pm
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
- Feb 7th, 2024 9:01 pm
Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Feb 7th, 2024 1:30 pm
Why Earnings Season Could Be Great for Ascendis Pharma (ASND)
- Feb 6th, 2024 1:46 pm
Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024
- Jan 31st, 2024 9:15 pm
Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism
- Jan 31st, 2024 9:01 pm
New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors
- Jan 29th, 2024 1:30 pm
Scroll